Silica

PubMed ID: 35152464

Large pulpotomy trial with calcium‑silicate materials showed ~92% 1‑year success (consistent repair outcomes).

PubMed ID: 25465773

Smectite/iodine cream substantially improved oral mucositis scores and shortened repair time—direct tissue‑repair benefit.

PubMed ID: 16764130

MTA (silicate cement) achieved clinical/histologic success in direct pulp capping, indicating improved local tissue repair in dental pulp.

PubMed ID: 17309744

Clinical RCT: calcium-silicate (MTA) had superior pulpal healing and hard-tissue formation vs formocresol — direct evidence of improved local tissue repair with a silicate material.

PubMed ID: 17956562

MTA pulp capping produced less inflammation and consistently formed protective hard tissue, indicating improved tissue-repair outcomes after application of a silicate-based agent.

PubMed ID: 17555692

Clinical dental trial showing high treatment success and hard-tissue barrier formation with MTA (silicate-containing), indicating improved tissue repair in that setting.

PubMed ID: 17305695

Apexification with MTA achieved healing in ~81% of cases — clinical tissue-repair outcome.

PubMed ID: 19134038

Clinical RCT showing much better periapical healing with an MTA root‑end filling — strong evidence of silicate‑containing material aiding repair in dental tissues.

PubMed ID: 19134040

High frequency of dentinal hard‑tissue bridge formation with MTA formulations shows repair promotion by calcium‑silicate materials.

PubMed ID: 20951286

Human pulp‑capping trial with improved dentinal bridge and reduced inflammation — direct tissue repair evidence.

PubMed ID: 21070705

MTA showed superior radiographic outcomes in pulpotomy (clinical evidence of improved pulp/tissue repair; material is calcium‑silicate based).

PubMed ID: 21703067

MTA pulpotomy trial demonstrating high success and reparative dentine — good evidence for tissue‑repair effects of a calcium‑silicate material in dentistry.

PubMed ID: 22048576

MTA showed superior clinical, radiographic and histologic outcomes in deciduous teeth versus formocresol — supports improved tissue repair with silicate‑containing material.

PubMed ID: 22762173

Higher pulpotomy success rates with MTA indicate better clinical tissue repair outcomes.

PubMed ID: 22838228

MTA significantly accelerated hard-tissue healing (apical barrier formation) in immature necrotic teeth — strong local tissue repair evidence.

PubMed ID: 23690353

MTA reduced pulp-capping failures vs CaOH, indicating improved dental tissue repair outcomes with a silicate-based material.

PubMed ID: 23756301

Strong clinical evidence that MTA (calcium silicate) gives better pulpal/tissue healing outcomes in primary molar pulpotomies.

PubMed ID: 24351693

Randomized clinical data showing MTA cements outperform calcium hydroxide for pulpotomy tissue repair over 24 months.

PubMed ID: 26898567

Strong long-term RCT evidence that MTA (calcium‑silicate) improves healing of endodontic tissues — direct evidence of improved tissue repair with a silicate-containing material (local application).

PubMed ID: 27472957

High success rates for pulpotomy using MTA materials indicate effective tissue repair in dental context.

PubMed ID: 27595722

Biodentine and MTA gave similarly high clinical/radiographic success in pulpotomies → supports effective tissue repair by silicate materials.

PubMed ID: 28917577

Direct pulp capping RCT with silicate materials showed high short‑term success—evidence of effective local tissue repair.

PubMed ID: 28673494

MTA (a calcium‑silicate material) produced markedly better 2‑year pulpotomy outcomes vs calcium hydroxide—strong clinical evidence of improved tissue repair in dental pulp.

PubMed ID: 29178761

5‑year outcomes with MTA/CEM show durable tissue healing in symptomatic vital teeth.

PubMed ID: 29275850

Biodentine non‑inferiority and lack of discoloration support its tissue‑repair profile in pulp capping.

PubMed ID: 28216271

100% clinical success at 12 months for direct pulp capping with silicate materials → solid tissue repair evidence.

PubMed ID: 31321573

MTA (calcium silicate) produced superior reduction in lesion volume after root‑end surgery vs empty cavity—good evidence of improved local tissue/bone repair with a silicate biomaterial.

PubMed ID: 31972958

Silica‑containing synthetic graft produced new bone formation and remodeling → direct regenerative/tissue repair evidence in human jaw defects.

PubMed ID: 34201328

MTA + bone graft produced best radiographic healing and defect fill in combined endo‑perio lesions (direct repair data).

PubMed ID: 34854987

Large RCT: calcium‑silicate pulpotomy produced clinical and radiographic healing equivalent to RCT (direct repair outcomes).

PubMed ID: 34192759

High success with silicate‑based materials in indirect pulp therapy (repair of dental tissues).

PubMed ID: 34706567

NaOCl lavage before MTA capping markedly improved pulp survival (tissue repair advantage with silicate material).

PubMed ID: 34321144

MTA superior to ferric sulfate for pulpotomy healing in primary molars (direct tissue repair evidence).

PubMed ID: 34657018

RCT: calcium‑silicate materials (Biodentine/MTA) gave high partial‑pulpotomy success and root development — direct evidence silica‑containing materials aid local tissue healing.

PubMed ID: 33683572

24‑month trial showed Biodentine and MTA (calcium‑silicate materials) produced high pulpotomy success — supports silica‑containing materials promoting tissue repair.

PubMed ID: 33483869

Premixed bioceramic showed improved clinical/radiographic performance sealing perforations (localized tissue repair).

PubMed ID: 33719478

Biodentine and MTA effective in immature molars — reparative dentine/root development (repair evidence).

PubMed ID: 35226769

Complete pulpotomy produced numerically higher success and less pain (clinical repair outcome with silicate material).

PubMed ID: 35075598

MTA partial pulpotomy had high clinical success over 18 months — indicates calcium‑silicate (silica‑related) materials support pulp healing.

PubMed ID: 35799339

Overall high clinical and radiographic success across pulp capping interventions; MTA‑based materials (silicate) were predictable — supports tissue repair.

PubMed ID: 37890614

NaOCl lavage markedly improved long‑term pulp survival in teeth treated with MTA (a calcium‑silicate material) — large clinical effect on pulp healing.

PubMed ID: 38219032

Calcium‑enriched (silica‑containing) cement kept more pulps alive after direct pulp capping than calcium hydroxide, demonstrating improved tissue repair in a dental clinical setting.

PubMed ID: 39702606

Selective removal with calcium‑silicate application improved dentin bridge formation and long‑term tooth vitality—supports improved tissue repair.

PubMed ID: 39215293

Clinical and biomarker data show pulpotomy with MTA/Biodentine supports pulp healing—evidence for improved tissue repair with silicate materials.

PubMed ID: 39862396

Biodentine produced greater dentin bridge formation—direct evidence of improved local hard tissue repair after silicate cement application.

PubMed ID: 39104340

iRoot BP Plus showed faster radiographic healing and higher success — supports improved local tissue repair using a bioceramic silicate material.

PubMed ID: 40234535

PRF plus MTA significantly increased dentin bridge formation vs MTA alone — strong evidence of improved tissue repair with a silicate material combined with biologic adjunct.

PubMed ID: 40691703

Strong radiographic and clinical healing after calcium‑silicate putty in immature nonvital incisors demonstrates robust tissue repair.

PubMed ID: 40457274

Bioactive glass‑containing ACTIVA produced stronger histologic reparative responses than MTA in early follow‑up.

PubMed ID: 41685840

Long‑term cohort showing high pulp survival after Biodentine direct pulp capping — durable tissue repair evidence for a silicate material.

PubMed ID: 26831423

Bentonite cream accelerated and increased complete healing of diaper dermatitis—direct topical tissue repair evidence.

PubMed ID: 16040019

Silica-containing microcarrier dressings produced substantially faster and more complete wound healing in diabetic foot ulcers (clinical evidence for improved tissue repair with a silica-containing material).

PubMed ID: 21336615

Kaolin pads produced markedly faster haemostasis in patients — clinically relevant to initial phase of tissue repair.

PubMed ID: 21476127

Kaolin haemostatic bandage provided much faster bleeding control after femoral access — strong clinical evidence for enhancing early repair environment.

PubMed ID: 24119521

Diosmectite+bFGF paste produced faster resolution of aphthous ulcers — clinical mucosal repair evidence.

PubMed ID: 29481992

Randomized clinical evidence that a silicate‑based dressing shortened healing times and increased effective healing rates after anorectal surgery.

PubMed ID: 31655876

Kaolin hemostatic pad trial demonstrated clinical hemostasis and less pain—direct device-level evidence for improving early wound management.

PubMed ID: 33219482

Topical gel containing dispersed silicon dioxide plus antioxidants greatly increased histological/cytological regression of cervical intraepithelial neoplasia — strong tissue repair/regression effect (multiple actives).

PubMed ID: 27595722

Clinical pulpotomy trial showed high success with calcium‑silicate materials (Biodentine/MTA) → supports faster/stronger local tissue repair outcomes.

PubMed ID: 25465773

Dioctahedral smectite cream significantly shortened oral mucositis repair time vs control (4.7 vs 8.8 days)—strong direct evidence for faster mucosal wound repair with a silicate product.

PubMed ID: 17309744

MTA (a calcium‑silicate material) used in pulpotomy produced superior hard-tissue outcomes and fewer adverse radiographic signs vs formocresol in children — strong clinical evidence that a silicate-based material enhances local hard-tissue repair (dental), relevant to wound/tissue repair mechanisms but local, not systemic.

PubMed ID: 17956562

Randomized trial: MTA pulp capping caused less inflammation and more consistent hard barrier formation than control, indicating accelerated/improved local tissue repair from a silicate material (good clinical evidence, local application).

PubMed ID: 17555692

In permanent molars with deep caries, MTA and calcium hydroxide had similarly high success rates and hard-tissue formation (dental healing outcome).

PubMed ID: 17305695

One-visit apexification with MTA resulted in ~81% healing at ≥12 months (direct clinical hard-tissue repair endpoint).

PubMed ID: 19629145

Portland cement (calcium silicate) performed similarly to MTA for pulpotomy — supports that silicate materials can mediate dento‑pulp repair.

PubMed ID: 19134038

RCT: MTA root‑end filling produced markedly better periapical healing vs smoothing gutta‑percha — shows a silicate‑containing material aiding tissue healing (indirect for systemic silica).

PubMed ID: 19134040

Two MTA formulations produced high rates of dentinal hard‑tissue bridging — evidence that calcium‑silicate materials support dental tissue repair.

PubMed ID: 20951286

Human pulp‑capping clinical trial with calcium‑silicate (silica‑containing) materials produced dentinal bridge formation and low inflammation—direct tissue repair outcome.

PubMed ID: 21070705

MTA (calcium‑silicate material) produced better radiographic healing after pulpotomy — indicates enhanced local tissue repair (clinical, indirect to silica).

PubMed ID: 21703067

Pulpotomy trial: MTA (a calcium‑silicate material) produced the highest 24‑month pulpotomy success and reparative dentine formation — supports silica‑containing material's tissue‑repair effects in dental pulp (moderate strength, material‑level evidence).

PubMed ID: 22048576

MTA pulpotomy study showing superior clinical/radiographic and histologic outcomes versus formocresol — indicates improved dental tissue repair with a calcium‑silicate material.

PubMed ID: 22762173

Higher clinical/radiographic success with MTA pulpotomy indicates improved local healing in dental pulp therapy.

PubMed ID: 22838228

Clinical trial: MTA produced significantly faster apical barrier formation and radiographic healing vs Ca(OH)2 — strong evidence for accelerated local hard-tissue healing.

PubMed ID: 23756301

Gray MTA (a calcium silicate cement) caused higher radiographic success and more dentin bridge formation in pulpotomies — direct evidence for faster/robust dental tissue repair at the application site.

PubMed ID: 24351693

MTA pulpotomy cements showed markedly better clinical/radiographic outcomes than calcium hydroxide over 24 months — supports superior local wound/tissue healing with silicate material.

PubMed ID: 26898567

6-year RCT: MTA (calcium‑silicate) increased healing rates of endodontically treated teeth vs control — solid evidence for local tissue repair mediated by a silicate material.

PubMed ID: 27472957

High 1-year success rates for partial pulpotomy with MTA materials indicate rapid/local reparative outcomes with silicate cements.

PubMed ID: 27891629

MTA (calcium-silicate) maintained pulp survival substantially better than calcium hydroxide over 3 years—strong clinical evidence of improved tissue repair in dental pulp.

PubMed ID: 28917577

Direct pulp capping trial with calcium silicate materials showed high short‑term success—evidence of effective local wound/pulp repair.

PubMed ID: 28673494

Randomized clinical trial: MTA (calcium‑silicate material) showed substantially higher 2‑year pulpotomy success vs calcium hydroxide → strong evidence of improved tissue healing in dental pulp context.

PubMed ID: 29178761

Full pulpotomy with MTA/CEM showed very high clinical success over 5 years — strong evidence of durable tissue healing by silicate‑containing materials.

PubMed ID: 29275850

Biodentine non‑inferior to ProRoot MTA in pulp capping with no discoloration — supports effective pulp healing (tissue repair).

PubMed ID: 28216271

Direct pulp capping with Biodentine/MTA achieved 100% clinical success at 12 months — indicates robust pulp tissue repair.

PubMed ID: 30292451

Multi‑year follow‑up found Biodentine and MTA produced favorable vital‑pulp therapy outcomes—consistent with durable tissue repair using silicate materials.

PubMed ID: 31321573

MTA (calcium silicate) in root‑end surgery led to greater periapical lesion volume reduction vs control—evidence of accelerated localized bone/tissue healing with a silicate biomaterial in surgical context.

PubMed ID: 34201328

MTA + bone graft produced best radiographic healing and defect fill in combined lesions (direct regenerative outcome).

PubMed ID: 34854987

Two‑year RCT: MTA/CEM (calcium‑silicate) pulpotomy matched or exceeded RCT for clinical/radiographic success — direct tissue repair evidence.

PubMed ID: 34192759

High success rates for silicate‑based IPL materials (Biodentine/Theracal) in pulp therapy (tissue repair in teeth).

PubMed ID: 34706567

NaOCl wound lavage before MTA capping substantially improved pulp survival (direct improvement in tissue repair outcome with silicate material).

PubMed ID: 34321144

MTA pulpotomy outperformed ferric sulfate clinically and radiographically at 12 months (direct tissue healing evidence).

PubMed ID: 34657018

Root length increases and high clinical success with Biodentine/MTA indicate accelerated healing processes.

PubMed ID: 33683572

High pulpotomy success and healing with Biodentine/MTA over 24 months suggests efficient pulp repair with silicate cements.

PubMed ID: 33483869

Premixed bioceramic sealed perforations with improved clinical/radiographic performance (local repair with silicate material).

PubMed ID: 33719478

Biodentine and MTA similarly effective in immature molar pulpotomy (healing/reparative outcomes).

PubMed ID: 36403208

Partial/full pulpotomy with Biodentine produced high 1‑year success in symptomatic teeth (tissue repair evidence).

PubMed ID: 35152464

Large trial: high 1‑year pulpotomy success with calcium‑silicate materials (consistent tissue repair data).

PubMed ID: 37890614

Marked improvement in pulp survival (functional outcome) with NaOCl + MTA supports a faster/better reparative process in dental pulp when silicate materials used.

PubMed ID: 39702606

Selective soft‑dentin removal plus calcium‑silicate application improved dentin bridge formation and long‑term tooth vitality—supports improved/ faster local tissue repair.

PubMed ID: 39862396

Biodentine produced larger radiographic dentin bridges vs Ca(OH)2 at 9 months—evidence of accelerated hard tissue repair after silicate cement application.

PubMed ID: 39104340

iRoot BP Plus produced faster periapical healing and higher 12‑month success vs MTA — evidence of faster local post‑surgical healing (dental context).

PubMed ID: 40234535

Adding PRF before MTA markedly increased dentin‑bridge formation versus MTA alone — clear evidence of accelerated local hard‑tissue repair (dentin bridge formation).

PubMed ID: 40691703

Premixed calcium‑silicate putty led to dramatic decreases in lesion size and increased bone radiodensity with clinical symptom resolution → strong evidence of accelerated local tissue repair.

PubMed ID: 40457274

ACTIVA (bioactive glass‑containing) induced stronger early fibrotic and mineralization marker responses than MTA in pulpal tissue histology → surrogate of faster reparative responses.

PubMed ID: 41685840

Biodentine (tricalcium silicate) direct pulp capping showed high pulp survival over multi‑year follow‑up — durable healing of pulp tissue.

PubMed ID: 26831423

Bentonite cream produced faster onset and higher complete healing rates of diaper dermatitis—direct topical wound/healing benefit.

PubMed ID: 38118067

Randomized trial: silica‑gel fiber dressing improved wound healing rates, reduced pain, and required fewer dressing changes in leg ulcers—direct evidence for faster/ better wound repair.

PubMed ID: 16040019

Randomized clinical use of silica-containing microcarrier dressings markedly accelerated healing of diabetic foot ulcers (large wound‑area reduction and fewer dressings needed).

PubMed ID: 21336615

Randomized trial: kaolin-impregnated pad markedly shortened haemostasis time vs manual compression (strong clinical evidence for faster bleeding control).

PubMed ID: 21476127

Clinical RCT: kaolin-based haemostatic bandage achieved much faster bleeding control after femoral procedures (strong, direct haemostasis evidence).

PubMed ID: 24119521

Topical diosmectite+bFGF reduced aphthous ulcer pain and size faster vs controls — direct clinical evidence of faster mucosal healing.

PubMed ID: 29481992

Randomized trial: silicate‑based wound dressing after anorectal surgery significantly shortened healing time across indications (~3–4 days faster) and increased effective rate.

PubMed ID: 31655876

Kaolin (an alumino‑silicate) hemostatic pad trial: directly relevant to wound hemostasis and faster local control of bleeding—concrete clinical device effect on early wound management.

PubMed ID: 33219482

Topical silicon dioxide gel (with antioxidants) markedly increased regression/clearance of CIN1/2 lesions — strong mucosal repair effect though multiple actives present.

PubMed ID: 34285282

Well‑controlled human trial: clinoptilolite greatly reduced GI lead uptake and urinary tracer excretion (direct mineral/toxicant sequestration evidence).

PubMed ID: 40618849

Large trial: SZC improved maintenance of normokalemia substantially over 12 months—robust evidence for mineral (potassium) balance.

PubMed ID: 25415807

Sodium zirconium cyclosilicate (a cyclosilicate) produced rapid, dose‑dependent reductions in serum potassium—direct mineral‑balance effect (drug context).

PubMed ID: 26011677

Sodium zirconium cyclosilicate normalized and maintained serum potassium in HF patients — robust clinical evidence of silicate-based mineral binding affecting electrolyte balance.

PubMed ID: 25651363

Zirconium silicate (ZS-9) in CKD patients produced rapid, dose-dependent, clinically meaningful reductions in serum potassium — strong evidence that a silicate compound can alter systemic mineral balance (drug context).

PubMed ID: 31201218

Direct: study of sodium zirconium cyclosilicate (a silicate-containing drug) produced large increases in rates of maintaining normal predialysis potassium—strong and specific mineral-balance effect.

PubMed ID: 31791288

Zirconium cyclosilicate (a cyclosilicate drug) rapidly lowered serum potassium in patients—demonstrates that a silicate compound can alter systemic electrolyte balance, but this is a drug (not dietary silica) and effect is potassium‑specific.

PubMed ID: 37385905

SZC improved predialysis normokalemia in dialysis patients—supports effect of a silicate compound on mineral balance in that population.

PubMed ID: 39566872

SZC enabled maintenance of normokalemia and continued spironolactone dosing—strong clinical evidence for mineral (potassium) balance using a silicate medication.

PubMed ID: 39112102

Phase III trial: sodium zirconium cyclosilicate (a crystalline silicate binder) dose‑dependently lowered and maintained serum potassium—direct evidence of a silicate compound affecting mineral (K+) balance.

PubMed ID: 40329202

SZC normalized potassium faster than sodium polystyrene sulfonate in hemodialysis patients—strong evidence for improving mineral/electrolyte balance (drug is a silicate compound but not dietary silica).

PubMed ID: 33183068

PMA‑zeolite changed bone turnover markers and increased BMD — indicates altered mineral homeostasis favoring bone retention.

PubMed ID: 16553280

ASI supplementation increased tibial ash mineral content and bone mineral density in quail — direct evidence of improved mineralization from a silicon-containing supplement in animals.

PubMed ID: 15359356

Bicarbonate-rich mineral water higher in silica improved ionized calcium and lowered PTH and bone-resorption markers, indicating improved mineral handling; confounded by multiple minerals.

PubMed ID: 18795515

NovaMin (calcium sodium phosphosilicate) dentifrice produced mineral deposition and reduced dentin sensitivity—strong direct evidence of silicate-driven local mineralization (most relevant study here).

PubMed ID: 21207920

NovaMin (bioactive glass) dentifrice induced mineral deposition (progressive dentin mineralization) in a large RCT — strong topical mineral‑balance effect in the oral cavity.

PubMed ID: 21207918

7.5% NovaMin (calcium sodium phosphosilicate bioactive glass) deposited mineral and reduced dentin sensitivity in humans — direct evidence of silica-containing material promoting mineral deposition.

PubMed ID: 21750917

Human crossover trial: a silica‑containing fluoride dentifrice with fTCP produced clear, quantified improvements in enamel surface microhardness and mineral recovery — strong direct evidence for improved local mineralization.

PubMed ID: 21698987

Calcium‑sodium‑phosphosilicate (bioactive glass containing silica) reduced dentin hypersensitivity via remineralization mechanisms — solid evidence for enhanced local mineral balance in dentin.

PubMed ID: 23715201

Clinical trial of CSPS wash showed increased tubule occlusion and decreased tubular surface area—strong evidence for localized mineral deposition and improved mineral status in dentine.

PubMed ID: 39490411

SZC (a zirconium silicate compound) plus higher dialysate K markedly reduced arrhythmia rates by keeping serum K in target range—direct evidence of electrolyte/mineral management.

PubMed ID: 39969301

Perioperative SZC suppressed postoperative potassium rise and reduced hyperkalemia incidence—direct effect on serum potassium control.

PubMed ID: 40457274

ACTIVA (bioactive glass fillers) induced mineralization markers and early mineral deposition in pulp — indicative of mineral‑promoting activity.

PubMed ID: 41369796

NovaMin (calcium‑sodium‑phosphosilicate bioactive glass) paste produced sustained dentin/tubule occlusion and remineralization‑related desensitization.

PubMed ID: 25402495

Sodium zirconium cyclosilicate (a cyclosilicate) rapidly normalized and maintained lower serum potassium versus placebo—direct, large effect on systemic mineral (K+) balance.

PubMed ID: 38622759

SZC (a crystalline zirconium silicate) robustly maintained normokalemia and raised bicarbonate in CKD patients — direct, strong evidence of an agent with silicate chemistry affecting mineral/electrolyte balance.

PubMed ID: 34854987

Calcium‑silicate materials (MTA/CEM) produce robust reparative responses in dental connective tissues (direct tissue data).

PubMed ID: 34706567

Improved pulp survival with MTA indicates improved connective tissue preservation/recovery (direct).

PubMed ID: 34657018

Clinical root development and successful partial pulpotomy with calcium‑silicate materials imply support for odontogenic connective tissue formation.

PubMed ID: 16040019

Silica-containing microcarrier dressing improved wound healing clinically; implies scaffold/support effects on connective tissue repair (material application).

PubMed ID: 40457274

ACTIVA with bioactive glass fillers increased pulp fibrosis and expression of fibronectin/osteopontin → direct tissue/connective‑matrix effects.

PubMed ID: 40691703

Large increases in bone radiodensity and lesion resolution indicate strong local connective and supporting tissue regeneration with calcium‑silicate putty.

PubMed ID: 37890614

Large improvement in pulp survival using MTA (silicate) after NaOCl lavage supports durable connective tissue outcome.

PubMed ID: 33683572

High pulpotomy success with Biodentine/MTA — indirect evidence these silicate materials support connective tissue health in pulp.

PubMed ID: 29481992

Silicate wound dressing accelerated healing and increased effective healing rate — supports connective tissue repair processes.

PubMed ID: 17956562

MTA capping led to more consistent protective hard layers and less inflammation — supports improved local connective/hard‑tissue response to a silicate material.

PubMed ID: 17309744

MTA (calcium silicate) improved pulpal hard-tissue outcomes, implying better local connective/hard-tissue formation around treated sites; relevant mechanistically though not evidence for systemic connective tissue support.

PubMed ID: 28056936

ch-OSA reduced cartilage-degradation biomarker changes in men and improved symptoms—supports connective tissue (cartilage) protection.

PubMed ID: 25465773

Smectite cream accelerated mucosal healing—indicative of improved local connective tissue repair/support from topical silicate formulation.

PubMed ID: 18547426

Direct human evidence: ch-OSA increased PINP (a marker of bone collagen formation) in a randomized trial.

PubMed ID: 16205932

ch-OSA raised serum silicon and improved skin/hair/nail measures—consistent with improved connective tissue support.

PubMed ID: 19134038

Improved periapical healing with MTA suggests silicate materials contribute to connective tissue repair processes in dental contexts.

PubMed ID: 19134040

High rates of dentinal hard‑tissue bridging with calcium‑silicate MTAs indicate support for mineralized tissue formation from silicate materials.

PubMed ID: 21703067

MTA (calcium‑silicate) pulpotomy data show reparative dentine formation and clinical success, implying connective‑tissue reparative effects of a silicate material (indirect evidence for silica's role).

PubMed ID: 23444134

Silicate-containing bone graft (SiCaP) achieved durable fusion and clinical improvement — supports hard connective tissue remodeling.

PubMed ID: 25073446

SiO2-matrix graft (NanoBone) produced higher implant torque values, implying improved bone/soft-tissue support around implants.

PubMed ID: 26898567

Calcium‑silicate dental cements produced better healing in dental connective tissues (local application) — relevant evidence that silicate compounds can support connective tissue repair locally.

PubMed ID: 27595722

High clinical success of calcium‑silicate pulpotomy materials suggests support for local connective‑tissue healing (clinical evidence).

PubMed ID: 28673494

Superior pulpotomy outcomes with MTA (calcium silicate) indicate improved connective tissue healing/regeneration in the dental pulp context.

PubMed ID: 31972958

Histology from a silica‑containing bone substitute showed new bone and osteoid activity — indicates support for connective/mineralized tissue regeneration.

PubMed ID: 34201328

MTA + bone graft achieved full defect fill (connective tissue/bone interface regeneration).

PubMed ID: 22068184

Polishing with pumice (a silicate abrasive) reduced plaque/calculus in vivo, which can support gingival health (topical, moderate relevance).

PubMed ID: 30620870

Same active formulation (silica base) significantly reduced overnight malodor, reflecting improved oral environment relevant to gum/scalp health.

PubMed ID: 34201328

Combined endodontic‑periodontal treatment with calcium‑silicate (MTA) + graft achieved superior radiographic healing of periodontal defects (direct dental tissue relevance).

PubMed ID: 23690353

MTA (silicate-based) performed better than CaOH for direct pulp capping with fewer failures—supports dental/pulpal tissue health which is relevant to oral health.

PubMed ID: 25666010

Pulpotomy trial in primary molars shows superior clinical/radiographic success with MTA (calcium‑silicate) — supports benefit of silicate-containing dental material for pulpal/periapical health.

PubMed ID: 26898567

Long-term randomized data show higher healing rates with MTA (a calcium‑silicate dental material) in root-end surgery — relevant to local dental tissue healing and gum/periapical health (local application, not systemic supplement).

PubMed ID: 8534381

Silica‑based dentifrice (with pyrophosphate/polymer) reduced supragingival calculus by ~54% vs placebo—direct clinical improvement that should benefit gum health (silica is vehicle, but outcome relevant).

PubMed ID: 17760546

CHX gel in a silica vehicle study showed increased CHX-coated silica persistence on root surfaces, supporting substantivity that could aid gum health.

PubMed ID: 11695208

Silica-grade dentifrice produced a substantial (≈34%) reduction in supragingival calculus versus control at 8 weeks; calculus control is directly relevant to gum health, though formulation contained other actives (triclosan/copolymer), so silica's specific role is uncertain.

PubMed ID: 18277739

2‑month RCT showed therapeutic mouthrinse and/or power toothbrush reduced plaque and tended to improve gingivitis (direct oral-health benefit).

PubMed ID: 10825856

12‑week clinical dentifrice trial showing ~34.6% reduction in supragingival calculus vs control; formulation likely silica‑containing so relevant to gum health (ingredient attribution limited).

PubMed ID: 10518859

Direct 12‑week clinical trial: a silica‑based tartar-control toothpaste produced a large, significant reduction in supragingival calculus—plausibly beneficial for gum health though attribution to silica alone is limited.

PubMed ID: 10518862

Human trial comparing abrasives found hydrated‑silica dentifrice removed plaque (58–68% range) in a 1‑minute brush; plaque reduction is directly relevant to gum health.

PubMed ID: 11695209

Toothpaste contained a high‑cleaning silica grade and showed significant anticalculus effect; silica likely contributed mechanically though formulation confounds attribution.

PubMed ID: 25465773

Silicate clay/iodine cream significantly improved oral mucositis healing—direct topical benefit to oral mucosa that relates to gum health.

PubMed ID: 30620868

RCT: toothpastes (zinc + arginine in a silica abrasive base) produced sustained 12‑hour reductions in oral bacteria across sites—directly relevant to gum health by reducing bacterial load.

PubMed ID: 30620869

Large clinical trial: zinc+arginine dentifrice (silica base) produced substantial reductions in gingivitis indices over 6 months → directly relevant to gum health.

PubMed ID: 28043751

Silicate-substituted CaP grafts integrated into bone tunnels and supported lamellar bone formation (human RCT of silicate-containing graft).

PubMed ID: 25073446

NanoBone (SiO2 matrix) produced substantially higher drill and insertion torque vs native/bovine bone—direct biomechanical evidence of denser bone regeneration.

PubMed ID: 23444134

SiCaP (silicate-containing bone graft) produced comparable long-term spinal fusion → direct support for bone-strength outcomes.

PubMed ID: 15359356

Bicarbonate-rich mineral water with higher silica was associated with increased ionized Ca, decreased PTH and reduced urinary bone-resorption markers—supports bone strength though multiple minerals confound attribution to silica.

PubMed ID: 18547426

Human randomized trial of ch-OSA (soluble silica) in osteopenic women: increased bone collagen marker (PINP) and a small but significant femoral neck BMD improvement in a subgroup.

PubMed ID: 16553280

Arginine‑silicate‑inositol (silicon-containing) in quail produced dose-dependent increases in bone mineral density and tibial ash mineral content (animal evidence supporting bone-strength effects).

PubMed ID: 34201328

Calcium‑silicate (MTA) + bone graft produced complete radiographic defect fill (jaw bone healing → bone strength proxy).

PubMed ID: 40691703

Premixed calcium‑silicate putty produced large increases in periapical bone radiodensity and marked lesion size reduction → local bone repair effect.

PubMed ID: 33183068

Randomized human trial: PMA‑zeolite oral treatment increased BMD vs placebo over 12 months (direct bone outcome).

PubMed ID: 38877464

NanoBone® contains a silica‑gel matrix used for ridge augmentation—directly relevant to bone grafting/augmentation outcomes.

PubMed ID: 31972958

Human RCT of a synthetic graft containing silica gel showed progressive resorption and replacement by new bone (histology → new bone formation).

PubMed ID: 15529609

Diosmectite markedly reduced diarrhea symptoms in chronic functional diarrhea—this would directly reduce fluid losses and support hydration retention.

PubMed ID: 38118067

Silica‑gel fiber dressing likely acts as a moisture‑balancing dressing and resulted in better wound outcomes—supports local hydration management in wounds.

PubMed ID: 17873673

Two-week RCT showed an oxygenated glycerol triester spray improved dry-mouth symptoms (reduced dryness), a direct hydration-retention benefit for the oral mucosa.

PubMed ID: 1488694

Dioctahedral smectite plus ORS halved average diarrhea duration and greatly reduced prolonged diarrhea vs ORS alone—clinically important effect on fluid loss and hydration (aluminosilicate related to silica).

PubMed ID: 8229544

Dioctahedral smectite plus ORS shortened diarrhea duration and reduced stool frequency compared with placebo—leads directly to improved fluid retention and hydration status in children (smectite = aluminosilicate clay; indirect to elemental silica).

PubMed ID: 7825006

Smectite added to rehydration therapy doubled the 72‑hour cure rate and reduced prolonged diarrhea—strong evidence of improved hydration outcomes with a silicate clay adjunct.

PubMed ID: 1750747

Smectite-treated infants resolved diarrhea faster than placebo, implying improved fluid/fluid-loss control and hydration (aluminosilicate; indirect to silica).

PubMed ID: 16205932

Randomized placebo-controlled trial showed significant improvements in skin surface roughness measures (Rt, Rm, Rz) after ch-OSA.

PubMed ID: 26831423

RCT in infants: bentonite (silicate clay) produced faster and more complete resolution of diaper dermatitis vs calendula—direct improvement of skin appearance.

PubMed ID: 41347526

Bentonite (an aluminosilicate clay) + extract face mask produced large clinically measured reductions in acne lesions and severity → clear skin appearance benefit.

PubMed ID: 16428147

Randomized, placebo‑controlled human trial of topical silicic acid showed significant reductions in non‑inflammatory acne lesions, total lesions and sebum output — direct human skin appearance benefit.

PubMed ID: 9283994

Small randomized pilot: oral/topical silicic acid produced clinically reported improvements in psoriatic skin lesions — direct clinical signal for skin appearance.

PubMed ID: 8854287

Randomized trial: topical silica gel produced large, significant reductions in acne lesions and sebum — directly improves skin appearance.

PubMed ID: 28613284

Activated micronized zeolite (an aluminosilicate) produced antioxidant effects comparable to vitamin E in smokers — antioxidant activity can support healthy aging.

PubMed ID: 18547426

Improved bone collagen formation and small femoral BMD benefit in older/osteopenic women suggests potential contribution to musculoskeletal aspects of healthy aging.

PubMed ID: 16205932

ch-OSA improved skin surface measures and reduced hair/nail brittleness—outcomes consistent with a contribution to healthy-aging appearance/function.

PubMed ID: 34285282

Clinoptilolite markedly reduced GI lead uptake (lower toxic burden can contribute to healthier aging).

PubMed ID: 17960402

9‑month RCT of choline-stabilized orthosilicic acid (ch-OSA) showed increased urinary Si and improvements in hair tensile properties and cross-sectional area.

PubMed ID: 16205932

ch-OSA produced statistically and clinically meaningful reductions in nail brittleness (VAS) over 20 weeks.

PubMed ID: 1286738

ViviScal contains a silica compound and produced large, significant increases in non-vellus hair and clinical/histologic cure—direct evidence linking a silica-containing product to improved hair.

PubMed ID: 9283994

In the pilot, nail onychopathy improved (5 of 10 evaluable patients 'cured'), a direct clinical signal that silicic acid benefited nails.

PubMed ID: 36471204

Bioactive glass spacer had comparable pain outcomes and less subsidence, relevant to post‑fusion comfort.

PubMed ID: 9283994

Approximately 50% reduction in joint pain reported in evaluable patients following oral/topical silicic acid — direct patient‑reported improvement in joint comfort.

PubMed ID: 28056936

Male subgroup experienced reduced WOMAC pain/stiffness with ch-OSA and lower cartilage-degradation biomarker changes—supports increased joint comfort.

PubMed ID: 17960402

ch-OSA RCT showed smaller declines in hair elastic gradient and break load versus placebo, indicating reduced hair fragility/breakage.

PubMed ID: 16205932

Trial reported reduced hair brittleness and subjective hair benefits vs placebo, implying less hair breakage.

PubMed ID: 1286738

ViviScal (contains silica compound) produced large improvements in non-vellus hair counts and histology, consistent with reduced fragility/breakage; multi-ingredient product limits attribution solely to silica.

PubMed ID: 36471204

Silica‑containing fusion spacer reduced subsidence and had similar pain/fusion — relevant to postoperative joint/spine function.

PubMed ID: 28056936

Male subgroup in ch-OSA trial had clinically meaningful WOMAC improvements (total and stiffness), indicating better joint function/mobility.

PubMed ID: 33930939

PMA‑zeolite supplementation reduced some gut inflammation markers and altered microbiome (supports systemic resilience).

PubMed ID: 34285282

Clinoptilolite significantly reduced GI lead uptake (lower toxicant burden enhances systemic resilience).

PubMed ID: 16205932

Reduced hair brittleness and reported hair improvements with ch-OSA imply improvements in hair and scalp condition though scalp endpoints were not explicit.